RAHAYU ZULKAPLI

Ms. RAHAYU ZULKAPLI

Universiti Teknologi MARA, Shah Alam, Selangor, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RAHAYU ZULKAPLIRAHAYU ZULKAPLI
RAHAYU ZULKAPLI
SMSUHAILA ABD MUID
SUHAILA ABD MUID
SWSeok Mui Wang
Seok Mui Wang
NSNatassya Ezzaty Mohd Sabri
Natassya Ezzaty Mohd Sabri
Despite reports on the efficacy of proprotein convertase subtilisin-Kexin type 9 (PCSK9) inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti-atherogenic properties of PCSK9 inhibitors in reducing PCSK9 and atherogenesis biomarkers via the NF-ĸB and eNOS pathway has yet to be established. This study aimed to investigate the effects of PCSK9 inhibitors on PCSK9, targeted early atherogenesis biomarkers, and monocyte binding in stimulated human coronary artery endothelial cells (HCAEC). HCAEC were stimulated with lipopolysaccharides (LPS) and incubated with evolocumab and alirocumab. The protein and gene expression of PCSK9, interleukin-6 (IL-6), E-selectin, intercellular adhesion molecule 1 (ICAM-1), nuclear factor kappa B (NF-ĸB) p65, and endothelial nitric oxide synthase (eNOS) were measured using ELISA and QuantiGene plex, respectively. The binding of U937 monocytes to endothelial cell capacity was measured by the Rose Bengal method. The anti-atherogenic effects of evolocumab and alirocumab were contributed to by the downregulation of PCSK9, early atherogenesis biomarkers, and the significant inhibition of monocyte adhesion to the endothelial cells via the NF-ĸB and eNOS pathways. These suggest the beyond cholesterol-lowering beneficial effects of PCSK9 inhibitors in impeding atherogenesis during the initial phase of atherosclerotic plaque development, hence their potential role in preventing atherosclerosis-related complications.

23 July 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
RAHAYU ZULKAPLIRAHAYU ZULKAPLI
RAHAYU ZULKAPLI
SMSUHAILA ABD MUID
SUHAILA ABD MUID
SWSeok Mui Wang
Seok Mui Wang
MYMohd Yusmiaidil Putera Mohd Yusof
Mohd Yusmiaidil Putera Mohd Yusof
HNHapizah Nawawi
Hapizah Nawawi
Atherosclerosis is a complex inflammatory disease driven by endothelial dysfunction. However, most in vitro studies rely on lipopolysaccharide (LPS) or oxidized LDL (oxLDL) as stimulants, overlooking the pathogenic role of lipoprotein(a) [Lp(a)]. Lp(a) is an independent and genetically determined risk factor for cardiovascular disease (CVD), but its precise mechanisms in promoting endothelial activation, inflammation, and monocyte adhesion remain poorly understood. The underlying mechanisms remain unclear despite clinical evidence that PCSK9 inhibitors (PCSK9i) lower plasma Lp(a) levels. This study explores the critical role of Lp(a) in driving PCSK9 expression and atherogenesis biomarkers, evaluates the protective effects of PCSK9i on endothelial activation, dysfunction and inflammation in Lp(a)-stimulated human coronary artery endothelial cells (HCAECs), and investigates their potential to mitigate monocyte adhesion, a key process in early atherogenesis. HCAECs were stimulated with Lp(a) and treated with Alirocumab or Evolocumab. Cell viability was assessed using the MTS assay. The expression of PCSK9, inflammatory (IL-6, NF-κB p65), endothelial activation (E-selectin, ICAM-1), and endothelial function (eNOS) biomarkers were quantified using ELISA and QuantiGene plex assays. Monocyte adhesion to endothelial cells was measured using the Rose Bengal method. Lp(a) stimulation increased PCSK9, IL-6, ICAM-1, E-selectin, NF-κB p65, and reduced eNOS in HCAECs. Both Alirocumab and Evolocumab lowered PCSK9 protein levels, with Alirocumab showing more potent effects. Evolocumab consistently reduced PCSK9 gene expression, whereas Alirocumab elicited variable effects. IL-6 and NF-κB p65 were elevated by both inhibitors, especially Alirocumab. Both treatments reduced ICAM-1 and E-selectin proteins, but gene expression varied. eNOS expression improved only at high concentrations (100 µg/ml), particularly with Evolocumab. Monocyte adhesion decreased at lower doses of both inhibitors, suggesting protective effects against early atherogenesis. PCSK9i exhibits pleiotropic effects beyond lipid-lowering by modulating endothelial activation, inflammation, and monocyte adhesion in Lp(a)-stimulated HCAECs. These findings provide mechanistic insights into the potential atheroprotective properties of PCSK9i, highlighting their role in early atherogenesis prevention. Not applicable.

2 December 2025 in The Saudi Dental Journal
Verified
Journal Article
Open access
PDF file
RAHAYU ZULKAPLIRAHAYU ZULKAPLI
RAHAYU ZULKAPLI
FSFaezah Sabirin
Faezah Sabirin
ASAnis Najihah Salleh
Anis Najihah Salleh
NZNurul Zurain Fatiha Zulaidi
Nurul Zurain Fatiha Zulaidi
IRIman Nabilah Abd Rahim
Iman Nabilah Abd Rahim
MAMuhammad Nazirul Mubin Aziz
Muhammad Nazirul Mubin Aziz
This systematic review aims to evaluate the efficacy of probiotic interventions in the prevention of enamel demineralization, with a specific focus on randomized clinical trials (RCTs). A comprehensive literature search was conducted in the Cochrane Library, PubMed, Scopus, and Web of Science electronic databases, covering studies published until April 2025. The review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Article selection and data extraction were independently conducted, with methodological quality evaluated using the Jadad Score. A total of 34 RCTs were included, with 17 studies scoring 5 and 8 studies scoring 3 on the Jadad scale, indicating moderate to high methodological quality. The majority of the trials involved children aged 1 to 15 years, while eight studies focused on adult cohorts aged 18 to 65 years. Intervention durations varied from 6 days to 2 years. The most commonly used probiotic strains were Lactobacillus, Bifidobacterium, or a combination of both, delivered via dairy-based products, lozenges, mouth rinses, or probiotic tablets. Twenty-seven research studies demonstrated a significant reduction in the main cariogenic pathogen, Streptococcus mutans ( p < 0.05 – p < 0.001), while findings on Lactobacillus reduction, plaque index, gingival status, salivary pH, and buffering capacity were inconsistent across studies. Long-term studies (≥ 6 months) showed more sustained effects, emphasizing the need for continuous probiotic intake to maintain oral health benefits. The findings suggest that probiotic interventions may represent a potential approach for preventing enamel demineralization, primarily through their ability to reduce cariogenic bacteria and increase salivary pH.

RAHAYU ZULKAPLIRAHAYU ZULKAPLI
RAHAYU ZULKAPLI
Mohd Yusmiaidil Putera Mohd YusofMohd Yusmiaidil Putera Mohd Yusof
Mohd Yusmiaidil Putera Mohd Yusof
SMSUHAILA ABD MUID
SUHAILA ABD MUID
SWSeok Mui Wang
Seok Mui Wang
AKAl 'Aina Yuhainis Firus Khan
Al 'Aina Yuhainis Firus Khan
NSNatassya Ezzaty Mohd Sabri
Natassya Ezzaty Mohd Sabri
A systematic review was performed to identify all the related publications describing PCSK9 and atherogenesis biomarkers attenuation associated with a natural product and plant bioactive compounds in in vitro studies. This review emphasized the imprecision and quality of the included research rather than the detailed reporting of the results. Literature searches were conducted in Scopus, PubMed, and Science Direct from 2003 until 2021, following the Cochrane handbook. The screening of titles, abstracts, and full papers was performed by two independent reviewers, followed by data extraction and validity. Study quality and validity were assessed using the Imprecision Tool, Model, and Marker Validity Assessment that has been developed for basic science studies. A total of 403 articles were identified and 31 of those that met the inclusion criteria were selected. 13 different atherogenesis biomarkers in relation to PCSK9 were found, and the most studied biomarkers are LDLR, SREBP, and HNF1α. In terms of quality, our review suggests that the basic science study in investigating atherogenesis biomarkers is deficient in terms of imprecision and validity.

27 April 2026 in BMC Oral Health
Verified
Journal Article
Open access
RAHAYU ZULKAPLIRAHAYU ZULKAPLI
RAHAYU ZULKAPLI
NSNusaibah Sallehuddin
Nusaibah Sallehuddin
NONashuha Omar
Nashuha Omar
NZNorazreen Zakaria
Norazreen Zakaria
AAAdriana Hamiera Zainol Anuar
Adriana Hamiera Zainol Anuar
MYMohd Yusmiaidil Putera Mohd Yusof
Mohd Yusmiaidil Putera Mohd Yusof
This systematic review and meta-analysis aimed to explore the biomarker profiles in adults diagnosed with periodontitis (PD) and coronary artery disease (CAD). Identifying shared biomarkers is crucial for clarifying the biological link between these two common inflammatory diseases, improving early risk detection, and supporting more integrated approaches to managing oral and cardiovascular health. A comprehensive literature search was conducted in Scopus, PubMed, and Web of Science, covering studies published up to December 2024, in accordance with Cochrane handbook guidelines. The study population consisted of adults diagnosed with PD and either confirmed CAD or cardiovascular risk indicators. The eligibility criteria required original full articles in English that assessed quantitative biomarker levels in individuals with both conditions compared to controls. The study design included observational (n = 14) and randomized controlled trials (n = 6). A random-effects meta-analysis was performed, and heterogeneity was assessed using the I² statistic. A total of 3,245 records were identified from three databases: PubMed (n = 737), Scopus (n = 1241), and Web of Science (n = 1267). The most frequently reported biomarkers among individuals with both PD and CAD were C-reactive protein (CRP/hs-CRP) and interleukin-6 (IL-6), followed by interleukin-1β, interleukin-8, and tumour necrosis factor-alpha. Five studies were included in the primary pooled meta-analysis for CRP analyses, that showed a significant pooled effect (SMD = 0.501; p = 0.001), while three studies stated that IL-6 showed no significant association (SMD = 0.166; p = 0.240). Overall, studies demonstrated elevated systemic inflammatory biomarkers in individuals with both conditions. The findings suggest a potential association between chronic PD and elevated systemic inflammatory biomarkers in individuals with CAD. In particular, CRP was consistently reported across several studies, although the strength and significance of biomarker associations varied. These results indicate that periodontal inflammation may contribute to systemic inflammatory responses relevant to cardiovascular pathology; however, current evidence remains insufficient to establish causality. Further well-designed longitudinal and interventional studies are required to clarify the clinical significance of this relationship. The online version contains supplementary material available at 10.1186/s12903-026-08407-2.

22 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RAHAYU ZULKAPLIRAHAYU ZULKAPLI
RAHAYU ZULKAPLI
SMSuhaila Abd Muid
Suhaila Abd Muid
SWSeok Mui Wang
Seok Mui Wang
ARAhmad Bakhtiar Md Radzi
Ahmad Bakhtiar Md Radzi
KIKhairul Shafiq Ibrahim
Khairul Shafiq Ibrahim
HNHapizah Nawawi
Hapizah Nawawi
Coronary artery disease (CAD) has been associated with elevated Lp(a) levels, yet the mechanism driving the pro-atherogenic and inflammatory effects remains unclear. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of lipid metabolism with emerging roles in vascular inflammation. This study explored the relationship between Lp (a) and PCSK9 in an Asian cohort with angiogram-proven premature CAD (AP-pCAD), with and without familial hypercholesterolemia (FH). Patients were recruited from Cardiology and Specialist Lipid Clinics; grouped into pCAD with FH ( n = 70), pCAD without FH ( n = 65), and normal controls (G3; n = 69). FH was clinically diagnosed using the Dutch Lipid Clinic Network. Lp(a) and PCSK9 levels were measured using an automated chemistry analyser and ELISA. Lp(a) and PCSK9 levels were significantly higher in pCAD groups compared to controls. No significant correlation between Lp(a) and PCSK9 was observed in individual pCAD subgroups (G1 or G2); a weak positive correlation was found in the normal control group (G3; r = 0.366, p = 0.019). In multivariate analysis, Lp(a) emerged as a significant independent predictor of pCAD (adjusted OR: 5.036, p = 0.015). In conclusion, Lp(a) independently predicts pCAD, while its association with PCSK9 appears modest and context-dependent, suggesting a more complex interplay possibly influenced by lipid-lowering therapy such as statin use.